AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
From Iron Dome to Arrow missiles, unpaid bills accumulate in Israel’s defense sector
2
The 50 most promising Israeli startups - 2026
3
Five bidders advance in Nice’s $2.5 billion Actimize sale process
4
“Israel will remain a cyber powerhouse for the next decade”
5
SanDisk’s second act: An AI boom, a $160 billion valuation, and a deep Israeli thread
More news

Compugen

5 stories about Compugen
מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
נאסדק

Compugen Falls 17% on Employee Cuts Announcement

27.02.19|Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
ענת כהן-דייג מנכ"לית קומפיוג'ן

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

12.10.18|Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
נאסדק נאסד"ק ניו יורק בורסה בועה

Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering

17.06.18|Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
ענת כהן-דייג מנכ"לית קומפיוג'ן

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen

03.04.18|Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen